AFT gains Australian registration for intravenous Maxigesic

AFT gains Australian registration for intravenous Maxigesic
Jenny Ruth
By Jenny Ruth July 24 (BusinessDesk) - AFT Pharmaceuticals says it has successfully registered the intravenous form of its Maxigesic medication with Australia’s Therapeutic Goods Administration. The intravenous product contains 1,000 milligrams of paracetamol and 300mg of ibuprofen in a 100 millilitre solution. The company says it expects to sell the product in Australia during the year ending March 2020 and the registration “clears the way for regulatory filings in a number of other territories including but not limited to Mexico, Sou...

More Services

$1.65b project to simplify switching banks a 'flop'
Finance

$1.65b project to simplify switching banks a 'flop'

Open banking has hindered competition rather than helping it, says lobby.

AAP 04 Jul 2024
Hundreds of ECE centres backtracking on pay parity
Policy

Hundreds of ECE centres backtracking on pay parity

96% of daycares have opted into pay parity, but govt funding doesn't match the costs.

Demand pricing may be coming to a movie theatre near you
Markets

Demand pricing may be coming to a movie theatre near you

NZX-listed Vista is rolling out a suite of AI innovations.

Govt 'will consult' on NZ Post review, minister says
Services

Govt 'will consult' on NZ Post review, minister says

The deadline for a review of the postal service is up this month.

Maria Slade 14 Jun 2024